Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001461 · ClinicalTrials.gov registry record
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme
A clinical trial of Atherosclerosis and Coronary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 209
- Enrollment target
- 1
- Study location
NCT00001461: Completed study of Atherosclerosis and Coronary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001461 is a study of Atherosclerosis and Coronary Disease that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 209 participants, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001461, a study of Atherosclerosis and Coronary Disease, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 209 participants
- Enrollment target
- 1
- Study location
Study Summary
The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This substance functions to keep blood vessels relaxed and to prevent blood from clotting inside the vessels. Studies done by researchers in the Cardiology Branch of the National Heart, Lung and Blood Institute have shown that nitric oxide activity may be lower in patients with hardening of the arteries (atherosclerosis) and risk factors for atherosclerosis. Another substance released by the cells of the endothelium is called bradykinin. It functions to stimulate the production of nitric oxide. Therefore bradykinin is also responsible for the relaxation and widening of blood vessels. An enzyme found in the blood called angiotensin-converting enzyme (ACE) inactivates baradykinin and thereby decreases the production of nitric oxide. The activity of ACE is determined by genetics and is different in each person. Medications that block ACE (ACE-inhibitors) may be useful for patients with high levels of ACE activity. This study is designed to determine; 1. The role of bradkinin in stimulating the production of nitric oxide 2. Whether ACE-inhibitors improve blood vessel relaxation caused by bradykinin 3. Whether ACE-inhibitors improve abnormal blood vessel relaxation 4. Whether ACE-inhibitors and bradykinin affect blood clotting 5. Whether blood vessel response to ACE-inhibitor and bradykinin depends on the patients genetic make-up
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 1995-03 |
| Est. Completion | 2001-04 |
What the finished NCT00001461 record still lists
NCT00001461 is an observational study that tracks outcomes without assigning an intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00001461 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001461 about?
NCT00001461 is a clinical study titled "Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme". The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This ...
What is the current status of trial NCT00001461?
This trial is currently completed. The enrollment target is 209 participants. The study started on 1995-03. Estimated completion is 2001-04.
What conditions does trial NCT00001461 study?
This clinical trial studies the following conditions: Atherosclerosis, Coronary Disease.
Who is sponsoring clinical trial NCT00001461?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001461 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001461's enrollment target sits among peer trials
209 36th of 69 higher than 34 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia